A Study of LX107 Gene Therapy in AIPL1-IRD Patients
Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
The subject and/or their guardian signs a written informed consent form and is w... [+3]
A history of ocular diseases that, in the investigator's judgment, may hinder th... [+11]